Travere Therapeutics (TVTX) Stock Jumps on Dec. 24, 2025: 52-Week High, FDA Catalyst Ahead, and Analyst Price Targets
Travere Therapeutics, Inc. (NASDAQ: TVTX) is ending 2025 with a bang. In the holiday-shortened U.S. trading session on Wednesday, December 24, 2025, TVTX surged sharply—pushing to fresh highs as investors recalibrated around two big themes: accelerating commercial execution for FILSPARI (sparsentan) and a looming FDA decision that could expand the drug into a second major kidney disease indication. StockAnalysis+2New York Stock Exchange+2 TVTX stock action on Dec. 24, 2025: a thin-session breakout with big numbers In early trading on Dec. 24, TVTX was up roughly 15% and changing hands around the low $40 range—an outsized move for a single session,